Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the
feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and
pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Ze-yang Ding, MD
Collaborators:
Chinese Cooperative Group of Liver Cancer Geneplus-Beijing Co. Ltd.